Company
IXICO PLC
LON:IXI
IXICO is no ordinary Imaging Contract Research Organisation (iCRO). By unlocking valuable insights into drug safety and efficacy, IXICO has built a highly respected global reputation and a 20-year track record as an end-to-end iCRO. IXICO addresses the complex biomarker challenges associated with neurodegenerative conditions, expertly managing and analysing neuroimaging clinical trials in areas such as Alzheimer’s, Parkinson’s, Huntington's and other rare diseases.
263 stories · page 1 of 3
Archive
Small Cap Feast - IXICO, and more...
23rd May 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners: No joiners today.Leavers: Hyve Group (HYVE) has left the Premium Segment of the London Stock Exchange.What’s
IXICO predicts return to sales growth from next year
Revenues will grow by at least 10% in 2024 said the statment
IXICO sees FY23 revenue in line with expectations; boosted by Alzheimer's developments
The year-end order book of £16mln reflected the signing of £12.6mln worth of new contracts over the year
IXICO says it is excited as Huntington’s consortium progresses
“We're excited to support this important project in our endeavour to bring novel imaging biomarkers into clinical trials," said Robin Wolz, IXICO chief scientific officer
IXICO raises profit guidance after strong second half
Orders are expected to top £15mln at the year-end
IXICO wins contract for phase 2 Parkinson's disease trial
The contract, signed with a leading European biopharmaceutical company, is the second study award with this client in the last 12 months
IXICO PLC expects strong second half; flags clinical trial impact
The neuro-imaging expert provided a trading statement alongside its interim results
IXICO lands its third Huntington’s Disease contract in two months
The latest commercial agreement is worth around £900,000
IXICO says first half represents period of consolidation
Chief executive Giulio Cerroni said he was "satisfied" with the performance over the past six months, delivering positive EBITDA and operating cash despite the halting of several important client trials
IXICO lands £800,000 Huntington's contract
It will support a global observational study to assess participants for the early detection of the condition
IXICO wins £800,000 Huntington's disease trial
This trial, which is expected to run for over five years, is the company's second study for the client after winning a 2021 contract following a Multiple System Atrophy study
IXICO hails the introduction of IXIQ.Ai, its new brain imaging technology
The new platform has been developed and validated in collaboration with academic and pharma partners, the company said
Ixico names Dr Lynne Hughes as senior therapeutic advisor
She most recently held a position at date science company IQVIA
IXICO to focus on trials framework as dementia collaboration enters second phase
Dementias Platform UK (DPUK) is an industry and academic collaborative body focused on finding ways to treat and prevent the disease
IXICO names new non-executive director
Rogers previously held senior positions at GlaxoSmithKline
IXICO reports 34% EBITDA growth and looks forward to new launches
In the current year the board is managing the challenges from the recent halt of a clinical trial and pursuing a focused investment programme
IXICO inks neuroimaging deal for phase III demyelinating disorder study
The trial will be conducted across 100 sites in 10 countries and is worth more than £1.0mln over seven years
IXICO says client suspends trial while it gathers more pre-clinical data
IXICO has been notified by a client of an indefinite halt to the client's clinical trial following the receipt of unexpected preclinical data.
IXICO boosted by strong end to financial year
“With an ageing population and the high unmet clinical need for new treatments for neurodegenerative diseases we remain very confident in the medium- and long-term opportunity"
IXICO lands US$750,000, two-year deal with top-five contract research group
The company will support a phase II Alzheimer's trial
IXICO lands Huntington’s disease clinical trial contract worth more than US$500,000
The latest deal is with an unnamed existing client
IXICO to provide expertise in clinical trial for nervous system disease treatment
The contract is worth more than US$500,000 over four years, investors were told
IXICO expects revenues to recover as Covid disruption eases
"We anticipate returning to a double-digit revenue growth trajectory as our 2022 financial year progresses”
IXICO earnings and revenues rise amid expanding order book
In its results for the six months ended March 31, the neuroscience-focused data analytics firm reported earnings of £0.9mln, up from £0.7mln a year ago, while revenues rose to £4.9mln to £4.6mln
IXICO awarded Alzheimer's trial expansion contract
The study is worth in excess of £1mln over five years
IXICO lands neuro-imaging contract worth £500,000
The company received the new work from an existing client
IXICO contract win is "strong endorsement" and supports growth strategy, says broker
“The focus on commercialisation and profitability by CEO Giulio Cerroni continues to deliver meaningful growth for the business and investors, and we would anticipate further positive momentum going forward”
IXICO wins neuroimaging contract with its largest client
The new Phase II acute ischemic stroke trial will be conducted across 50 sites in North America and Europe
IXICO reassures with trading update says Shore Capital
Company has a healthy order book and strong cash position
IXICO sales and orders rise despite COVID-19 disruption
The strong book to bill ratio for the period reflects the resilience of the operating model , the company said
IXICO links up with Microsoft to enhance AI platform
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
IXICO told Huntington's disease trial to stop
The decision followed an independent committee review of the potential benefit/risk profile
IXICO to use Microsoft's cloud-based AI infrastructure to scale-up
IXICO continues to scale up in the highly regulated clinical trials environment
IXICO announces second Alzheimer’s clinical trial contract in the space of a week
It will provide 'advanced solutions’ involving structural magnetic resonance imaging
IXICO brought in by new client to support Alzheimer's trial
Alzheimer’s affects an estimated 50mln people worldwide with devastating mental and physical consequences
IXICO lands £3.4mln trial contract
The company will provide operational services and advanced AI neuroimaging expertise
IXICO gets Huntington's disease contract over the line
The contract win was included in management's expectations of performance for the current financial year but adds to the company's strong order book
IXICO sees full-year earnings more than double amid record revenues
The neuroimaging data analytics firm also reported a 36% increase in its contracted order book to a record level of £21.7mln
IXICO lands £1.9mln follow-on contract with existing sponsor
The award recognises the company's long track record of research in the area of Huntington's disease
IXICO lands three new clinical trial contracts, reflecting its growing expertise in Alzheimer's disease
The group will carry out work on a phase I study, it has also signed an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial
IXICO secures new contracts in Huntington's disease clinical trials
The contracts include retrospective analysis of data sets for three Natural History Studies in Huntington's disease with a new large pharma customer and a multicentre, open-label Phase II study in Huntington's disease with an existing large
IXICO sees full-year underlying earnings more than double in fourth consecutive year of strong top-line growth
In a trading update, the group said earnings before interest, tax, depreciation, and amortisation should at least meet market expectations of £1.1mln (2019: £0.5mln)
IXICO teams up with NYU Langone Health to help in the quest to find a treatment for a rare degenerative neurological disorder
Dr Robin Wolz, senior vice president for science and innovation at IXICO, said: "This collaboration will help to accelerate the quest for new treatments for multiple system atrophy by bringing together some of the leading researchers in the